List of Excipients in Branded Drug CUBICIN RF

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Merck Sharp & Dohme LLC	CUBICIN RF	daptomycin	67919-012	SODIUM HYDROXIDE
Merck Sharp & Dohme LLC	CUBICIN RF	daptomycin	67919-012	SUCROSE

CUBICIN RF Excipient Strategy and Commercial Opportunities

Last updated: September 5, 2026

CUBICIN RF is an intravenous daptomycin product whose commercial value depends on more than the active ingredient. Its excipient system, lyophilized presentation, reconstitution profile, container-closure system, and hospital-use economics create opportunities for generic manufacturers, contract developers, excipient suppliers, and drug-delivery companies. The core formulation contains daptomycin, sucrose, and sodium hydroxide, with no antimicrobial preservative. The strongest opportunities are in reconstitution convenience, ready-to-use presentations, stability enhancement, vial optimization, and manufacturing-cost reduction.

What excipients are used in CUBICIN RF?

CUBICIN RF contains daptomycin as the active pharmaceutical ingredient, sucrose as a stabilizing and bulking excipient, and sodium hydroxide for pH adjustment. The product is supplied as a sterile, preservative-free, lyophilized powder for intravenous infusion.[1]

Component	Function in CUBICIN RF	Commercial relevance
Daptomycin	Cyclic lipopeptide antibacterial	Calcium-dependent antibacterial activity
Sucrose	Lyoprotectant, stabilizer, and bulking agent	Supports cake structure and protein-like peptide stability
Sodium hydroxide	pH adjustment	Controls formulation pH and product performance
Sterile water for injection	Reconstitution vehicle	Required before administration
Sodium chloride injection	Dilution vehicle when used	Supports intravenous infusion after reconstitution

Daptomycin is sensitive to formulation conditions because it is a cyclic lipopeptide with amphiphilic properties. Its performance can be affected by pH, ionic strength, concentration, temperature, agitation, surface contact, and calcium availability. The excipient strategy therefore has to preserve chemical potency, physical stability, reconstitution behavior, and antibacterial activity.

The formulation does not rely on a preservative system. That limits the risk of preservative-related compatibility problems but places greater importance on aseptic manufacturing, vial integrity, and post-reconstitution handling.

Why is sucrose commercially important in CUBICIN RF?

Sucrose is the principal functional excipient in CUBICIN RF. In a lyophilized product, it can replace water around the drug during freezing and drying, reduce structural stress, and support a stable amorphous matrix. It also contributes to the appearance and mechanical integrity of the lyophilized cake.

For suppliers, the opportunity is concentrated in sterile, parenteral-grade sucrose with controlled bioburden, endotoxin, particulate, and trace-metal profiles. A pharmaceutical manufacturer may qualify multiple suppliers, but changing sucrose grade can require comparability work because the excipient can affect:

• Collapse temperature during lyophilization
• Cake appearance and shrinkage
• Reconstitution time
• Residual moisture
• Daptomycin degradation
• Subvisible particulate formation
• Container-closure interaction
• Long-term stability

A lower-cost sucrose source is commercially attractive only if it preserves the validated freeze-drying cycle and release profile. The value is therefore higher for a supplier offering technical support, compendial documentation, sterile handling, and reliable global supply than for a commodity supplier competing only on price.

What formulation opportunities exist for CUBICIN RF?

The largest formulation opportunity is to improve administration efficiency without changing daptomycin’s approved clinical use.

Reconstitution-time reduction

CUBICIN RF is supplied as a lyophilized powder that requires reconstitution before dilution and infusion. A generic or follow-on developer could target faster dissolution through:

• Optimized cake geometry
• Controlled pore structure
• Improved vial fill volume
• Modified sucrose concentration
• Excipients that reduce powder cohesion
• More efficient diluent delivery
• Revised headspace and stopper configuration

Any change must avoid foaming, aggregation, incomplete dissolution, excessive residual moisture, or increased particulate levels.

Ready-to-use or premixed presentations

A ready-to-use daptomycin infusion product could reduce pharmacy preparation time and occupational handling. Potential formats include:

• Premixed flexible infusion bags
• Dual-chamber containers
• Prefilled reconstitution devices
• Closed-system transfer presentations
• Pharmacy bulk packages
• Extended-stability refrigerated bags

The primary technical barrier is stability after reconstitution and dilution. A commercial product would need validated chemical and physical stability in the selected container, including compatibility with plastic materials, tubing, ports, and infusion devices.

A ready-to-use product may also face a different regulatory pathway from a conventional vial generic. A 505(j) ANDA generally requires pharmaceutical equivalence and bioequivalence to the reference product. A materially different dosage form, concentration, container, or administration method may require a 505(b)(2) application rather than a standard ANDA.[2]

Dose-size optimization

Daptomycin dosing is weight-based for some patients and indication-specific. The approved CUBICIN RF vial sizes can create unused drug when the calculated dose does not match the vial content. Opportunities include:

• Lower-strength vials for dose efficiency
• Larger pharmacy bulk containers
• Concentrated presentations
• Combination vial packs
• Weight-band packaging for institutional use

The commercial value depends on whether the revised presentation reduces discarded drug without increasing preparation complexity. Hospitals may accept a higher unit price if the product lowers total dose waste and pharmacist labor.

How strong is the formulation patent position for CUBICIN RF?

The active ingredient daptomycin has been known for decades, so commercial protection depends more heavily on formulation, manufacturing, dosage-form, and method-of-use rights than on basic composition-of-matter protection.

Relevant patent categories include:

Patent category	Potential subject matter	Commercial effect
Composition patents	Daptomycin or related lipopeptides	Basic exclusivity, generally historical for CUBICIN
Formulation patents	Stabilized lyophilized daptomycin	May delay or complicate generic substitution
Manufacturing patents	Fermentation, purification, drying, or impurity control	Can increase non-infringing process costs
Container patents	Vial, stopper, reconstitution, or delivery system	May affect alternative presentations
Method-of-use patents	Treatment of bacteremia, endocarditis, skin infections, or dosing regimens	Relevant to skinny-label and induced-infringement analysis
Stability patents	Extended post-reconstitution or diluted-product stability	Relevant to ready-to-use products

The Orange Book is the controlling public reference for patents submitted to FDA for an approved drug product. Developers evaluating CUBICIN RF should review the current listing for NDA 021572, identify each unexpired patent, and compare the proposed formulation and labeling against the listed claims.[3] Patent expiration analysis should separate expiration of the patent term from pediatric exclusivity, regulatory exclusivity, terminal disclaimers, and any court-ordered or settlement-based launch restrictions.

A formulation patent is commercially meaningful only if its claims cover the proposed product or an unavoidable manufacturing step. Broad claims directed to daptomycin generally may be less important than claims requiring a specific excipient ratio, pH, concentration, lyophilization profile, or stability period.

When does CUBICIN RF lose exclusivity?

CUBICIN RF's exclusivity analysis has four separate elements:

1. FDA regulatory exclusivity.
2. Orange Book-listed patent terms.
3. Litigation outcomes involving Paragraph IV certifications.
4. Contractual settlement dates between the reference sponsor and generic applicants.

FDA approved daptomycin injection under NDA 021572 in 2003. CUBICIN RF is the reformulated presentation associated with the daptomycin reference product and is marketed by Merck following its acquisition of Cubist Pharmaceuticals.[1,4]

The practical generic-entry date cannot be determined from the original approval date alone. A developer must establish whether a listed patent remains in force, whether it is challenged, whether the first Paragraph IV filer receives 180-day exclusivity, and whether a settlement agreement creates an agreed launch date.

What Paragraph IV risks affect CUBICIN RF?

A generic applicant may file a Paragraph IV certification stating that an Orange Book-listed patent is invalid, unenforceable, or will not be infringed by the proposed product. The reference sponsor can then bring patent litigation under the Hatch-Waxman Act. A timely infringement action can trigger a statutory stay of FDA approval for up to 30 months, subject to statutory exceptions and court developments.[2]

For an excipient-focused CUBICIN RF strategy, the principal Paragraph IV issues are likely to include:

• Whether the generic uses the same or an equivalent excipient system.
• Whether the proposed lyophilized cake falls within formulation claims.
• Whether the generic's pH and concentration overlap claim limitations.
• Whether stability data are generated using a patented method.
• Whether a different vial or stopper avoids container claims.
• Whether a skinny label omits patented indications or dosing instructions.

A formulation developer can reduce litigation exposure by designing around specific excipient ranges, avoiding claimed stability conditions, using a different container configuration, and documenting independent development. Those measures do not eliminate litigation risk where the reference patent claims are broad.

Which companies are challenging CUBICIN RF?

Generic daptomycin has been developed by multiple pharmaceutical manufacturers, including large generic companies and injectable-specialty manufacturers. Market participation depends on FDA approval status, product availability, manufacturing capacity, and litigation settlements rather than on an applicant's filing alone.

The relevant competitive set includes:

• ANDA applicants for daptomycin for injection.
• Contract manufacturers with sterile lyophilization capacity.
• Specialty injectable companies.
• Hospital-focused generic suppliers.
• Developers of premixed or ready-to-administer intravenous products.

A complete challenge map requires current FDA approval records, Orange Book certifications, federal docket data, and commercial availability data. FDA's Drugs@FDA database and Orange Book provide the primary regulatory sources.[3,5]

What manufacturing barriers affect CUBICIN RF competitors?

The main barrier is not the availability of sucrose or sodium hydroxide. It is reliable sterile production of a complex lyophilized lipopeptide product.

Key manufacturing risks include:

• Fermentation variability for daptomycin API
• Removal of related substances and residual process impurities
• Control of endotoxin and bioburden
• Adsorption to process-contact surfaces
• Foaming during bulk handling
• Incomplete or uneven lyophilization
• Particulate generation
• Stopper and vial compatibility
• Reconstitution variability
• Long-term stability under temperature excursions

A manufacturer with an established sterile lyophilization line can gain an important cost and timing advantage. Capacity for commercial-scale lyophilization, validated container-closure integrity testing, and reliable cold-chain distribution are more difficult to replicate than the excipient formula itself.

What commercial opportunities exist for excipient suppliers?

The most actionable opportunities are in supply assurance and formulation services rather than in selling a novel excipient alone.

Pharmaceutical-grade sucrose

Suppliers can compete through low-endotoxin grades, sterile supply, global inventory, and technical support for cycle development. Documentation covering elemental impurities, nitrosamines, residual solvents, microbial quality, and extractables can reduce customer qualification time.

Stabilizer screening

A development partner could screen trehalose, mannitol, amino acids, polymers, and surfactants as alternatives or complements to sucrose. The objective would be improved cake strength, lower reconstitution time, or better stability. Any new excipient may create a regulatory burden and can undermine ANDA comparability if it changes the reference formulation materially.

Container-closure systems

Vial, stopper, and reconstitution-device suppliers can target reduced adsorption, low particulate generation, and improved transfer efficiency. Closed-system devices may have value in hospital pharmacies even where the underlying drug formulation remains unchanged.

Contract development and manufacturing

CDMOs with sterile lyophilization, peptide or lipopeptide handling, and injectable packaging capability can support 505(j) and 505(b)(2) programs. The strongest commercial proposition is an integrated package covering formulation development, cycle development, analytical methods, process validation, regulatory support, and commercial fill-finish.

How does CUBICIN RF compare with competing intravenous antibiotics?

CUBICIN RF competes mainly on spectrum, dosing convenience, hospital familiarity, and total treatment cost. Its excipient system is relatively simple compared with products that require multiple stabilizers, preservatives, or complex delivery devices.

Product characteristic	CUBICIN RF	Commercial implication
Active ingredient	Daptomycin	Differentiated lipopeptide mechanism
Dosage form	Lyophilized intravenous powder	Requires pharmacy preparation
Preservative	None	Supports parenteral tolerability and compatibility
Primary stabilizer	Sucrose	Familiar, scalable excipient platform
Main delivery barrier	Reconstitution and infusion preparation	Opportunity for premixed products
Generic development route	Usually 505(j) for equivalent injection	Lower regulatory burden than a novel therapy, but formulation comparability remains important

What is the FDA regulatory status of CUBICIN RF?

CUBICIN RF is an FDA-approved prescription antibacterial administered by intravenous infusion. Its labeled indications include complicated skin and skin-structure infections and Staphylococcus aureus bloodstream infections, including right-sided infective endocarditis, subject to the approved labeling and age restrictions.[1]

A developer changing excipients, concentration, dosage form, or administration method should determine whether the product remains pharmaceutically equivalent to the reference product. A material formulation or delivery change can shift the program from an ANDA toward a 505(b)(2) application. FDA's product-specific guidance, labeling requirements, stability expectations, and injectable-product quality standards determine the practical development path.[2,6]

Key Takeaways

• CUBICIN RF uses daptomycin, sucrose, and sodium hydroxide in a preservative-free lyophilized intravenous presentation.
• Sucrose is the central excipient opportunity because it affects cake structure, stability, reconstitution, and manufacturing yield.
• The strongest product opportunities are faster reconstitution, ready-to-use infusion products, smaller dose sizes, and reduced vial waste.
• Generic developers must separate active-ingredient freedom to operate from formulation, manufacturing, container, and method-of-use patent risks.
• The Orange Book, Drugs@FDA, FDA product-specific guidance, and federal litigation records are required for a current entry-date and patent-risk assessment.
• Sterile lyophilization capacity, impurity control, container-closure validation, and stability data are the principal manufacturing barriers.
• Excipient suppliers can capture value through high-quality sucrose, technical documentation, formulation support, and integrated CDMO partnerships.

FAQs

Can sucrose be replaced in a generic CUBICIN RF product?

Yes, but replacement can affect pharmaceutical equivalence, lyophilization performance, stability, reconstitution, and regulatory classification. A different excipient system may require a 505(b)(2) strategy rather than a straightforward ANDA approach.

Is CUBICIN RF a biologic subject to biosimilar approval?

No. Daptomycin is a chemically defined antibacterial drug, not a biological product regulated through the biosimilar pathway. A follow-on product would generally be evaluated under the generic drug or 505(b)(2) framework.

Could a premixed daptomycin bag replace the CUBICIN RF vial?

It could compete commercially if it demonstrates adequate stability, container compatibility, sterility, labeling compliance, and an acceptable FDA regulatory pathway. The dosage form and administration differences may prevent traditional ANDA treatment.

Does the absence of a preservative create a commercial advantage?

Yes. A preservative-free presentation can simplify compatibility and tolerability considerations. It also increases the importance of aseptic processing, container integrity, and controlled post-reconstitution handling.

Which excipient has the highest near-term commercial value?

Parenteral-grade sucrose has the clearest near-term opportunity because it is central to the established formulation and can be supplied at scale. Higher-margin opportunities exist in sucrose qualification packages, lyophilization-cycle support, reconstitution devices, and ready-to-use delivery systems.

References

1. Merck & Co., Inc. (2023). CUBICIN RF (daptomycin for injection) prescribing information. U.S. Food and Drug Administration.

2. U.S. Food and Drug Administration. (2024). Abbreviated new drug application process under section 505(j) of the Federal Food, Drug, and Cosmetic Act. FDA.

3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.

4. Merck & Co., Inc. (2015). Annual report 2014. Merck.

5. U.S. Food and Drug Administration. (2024). Drugs@FDA: FDA-approved drugs. FDA.

6. U.S. Food and Drug Administration. (2023). Product-specific guidances for generic drug development. FDA.